GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29333
Submission : 2015-06-22
Status : Active
Type : IV
NDC Package Code : 55363-294
Start Marketing Date : 2015-04-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37061
Submission : 2022-04-20
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20526
Submission : 2007-05-11
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33045
Submission : 2018-08-06
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7940
Submission : 1989-02-21
Status : Active
Type : II
NDC Package Code : 68444-0003
Start Marketing Date : 2010-10-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (56kg/56kg)
Marketing Category : BULK INGREDIENT
FINISHED DOSAGE FORMULATIONS
Drug : ESTRADIOL
Dosage Form : TABLET; ORAL
Application Number : 40114
Country : US
Patented : No
Drug : LOXAPINE SUCCINATE
Dosage Form : CAPSULE; ORAL
Application Number : 72204
Country : US
Patented : No
Drug : LOXAPINE SUCCINATE
Dosage Form : CAPSULE; ORAL
Application Number : 72062
Country : US
Patented : No
Drug : VERAPAMIL HYDROCHLORIDE
Dosage Form : TABLET; ORAL
Application Number : 70995
Country : US
Patented : No
Drug : VERAPAMIL HYDROCHLORIDE
Dosage Form : TABLET; ORAL
Application Number : 70994
Country : US
Patented : No
HYDROCHLOROTHIAZIDE; TRIAMTERENE
Drug : TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Dosage Form : TABLET; ORAL
Application Number : 73449
Country : US
Patented : No
Drug : LOXAPINE SUCCINATE
Dosage Form : CAPSULE; ORAL
Application Number : 72205
Country : US
Patented : No
Drug : OLANZAPINE
Dosage Form : TABLET, ORALLY DISINTEGRATING; ORAL
Application Number : 203708
Country : US
Patented : No
Drug : LORAZEPAM
Dosage Form : TABLET; ORAL
Application Number : 203572
Country : US
Patented : No
Drug : ATIVAN
Dosage Form : TABLET; ORAL
Application Number : 17794
Country : US
Patented : No
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 23
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 45.28
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 20
Potency Unit : MG/5ML
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 45.8
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 4
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 21
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 5
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 40
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 40
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
POLACRILIN POTASSIUM
Route : ORAL
CAS : 65405552
UNII : 0BZ5A00FQU
Potency Amount : 10
Potency Unit : MG
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
EXCIPIENTS BY APPLICATIONS
Application : Disintegrants & Superdisintegrants
Excipient Details : It is used in tablet disintegration and taste masking of bitter drugs.
Application : Disintegrants & Superdisintegrants
Excipient Details : It is used as a disintegrating agent.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Polacrilin Potassium
Dosage Form : Capsule, Granule / Pellet, Orodispersible Tablet, Tablet
Grade : Oral
Category : Disintegrants & Superdisintegrants
Application : Disintegrants & Superdisintegrants
Excipient Details : PolyIon 909 is used as a disintegrant and dissolution enhancer in oral solids such as tablets, capsules, pellets, and orally disintegrating tablets.
Pharmacopoeia Ref : USPNF
Technical Specs : Contains 0.5 to 10% of tablet weight
Ingredient(s) : Polacrilin Potassium
Application : Taste Masking
Excipient Details : It is used in tablet disintegration and taste masking of bitter drugs.
Application : Taste Masking
Excipient Details : It is used as a disintegrating agent.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Polacrilin Potassium
Application : Taste Masking
Excipient Details : Wet Granulation and Direct Compression
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Polacrilin Potassium
MARKET PLACE
Reply
09 Dec 2023
Reply
31 May 2023
Reply
16 Dec 2021
Reply
11 Feb 2021
Reply
25 Mar 2020
Reply
14 Dec 2019
Reply
16 Mar 2019
REF. STANDARDS & IMPURITIES
CAS Number : 65405-55-2
Quantity Per Vial : 200
Sale Unit : mg
Price : $289.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1545500 / R08250